Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Michael L. Tidwell"'
Autor:
Amy M. Schuster, Jenna A. Van Fossen, Shubham Agrawal, Sicheng Wang, Elizabeth A. Mack, Michael L. Tidwell, Shelia R. Cotten
Publikováno v:
Transportation Research Interdisciplinary Perspectives, Vol 26, Iss , Pp 101164- (2024)
Automated vehicle (AV) adoption is anticipated to affect millions of motor vehicle operators, including gig drivers (platform-based ride-hailing and/or delivery drivers). The multidisciplinary body of research investigating worker attitudes towards a
Externí odkaz:
https://doaj.org/article/ca2c7b6bb07046328bcfaea7c16646f3
Autor:
Shubham Agrawal, Amy M. Schuster, Noah Britt, Elizabeth A. Mack, Michael L. Tidwell, Shelia R. Cotten
Publikováno v:
Technology in Society. 72:102186
Autor:
Michael L. Tidwell, Maria R. Baer, Mya S. Thein, Nora Oliver, Edward A. Sausville, Farin Kamangar, Briana Short, Vu H. Duong, Ashkan Emadi
Publikováno v:
Leukemia & Lymphoma. 56:2082-2086
Patients with acute leukemia develop venous thrombosis (VT) related to central venous catheters (CVCs). Anticoagulation (AC) in these patients who are thrombocytopenic and often coagulopathic is challenging. To evaluate the safety and efficacy of AC
Autor:
Emily J. Vannorsdall, Dan P. Zandberg, Bhavana Bhatnagar, Vu H. Duong, Qing Chen, Maria R. Baer, Michael L. Tidwell
Publikováno v:
Leukemia & Lymphoma. 56:1718-1722
The hypomethylating agents azacitidine and decitabine are standard therapy for myelodysplastic syndromes (MDS), and are often used to treat patients with acute myeloid leukemia (AML) unlikely to benefit from cytotoxic chemotherapy. Switching hypometh
Autor:
Michael L. Tidwell, Ching Chen, Maria R. Baer, Yi Ning, Ashkan Emadi, Feyruz V. Rassool, Theodore Stewart Gourdin, Vu H. Duong, Ying Zou
Publikováno v:
Cancer Genet
FLT3 internal tandem duplication (ITD) mutations are present in acute myeloid leukemia (AML) in 30% of patients with acute myeloid leukemia (AML), most commonly in those with a normal karyotype, and are associated with short relapse-free survival. Bo
Autor:
Theodore Stewart Gourdin, Michael L. Tidwell, Vu H. Duong, Ashkan Emadi, Ching Chen, Maria R. Baer, Edward A. Sausville, Bhavana Bhatnagar, Yi Ning
Publikováno v:
Leukemia & Lymphoma. 55:1533-1537
We retrospectively reviewed outcomes in 45 previously untreated patients with acute myeloid leukemia (AML) considered unfit for chemotherapy who were treated with 10-day courses of decitabine 20 mg/m(2) daily outside of a clinical trial, with no cut-
Autor:
Anthony D. Sung, Michael W. Evans, Maria R. Baer, Ivana Gojo, Judith E. Karp, Mark J. Levis, Michael L. Tidwell, Jacqueline Greer
Publikováno v:
Leukemia & Lymphoma. 53:660-664
CD4 count ≤200×10(6) cells/L has been identified as a predictor of short survival in HIV-associated acute myeloid leukemia (HIV-AML), but karyotype, which is the best predictor of survival in AML, has not been evaluated in HIV-AML patients. A retr
Autor:
Judith E. Karp, Roberto Pili, Ivana Gojo, Helen X. Chen, Jacqueline Greer, Michael L. Tidwell, Christopher D. Gocke, David Z. Qian, Lawrence E. Morris, Chuanfa Guo, James A. Zwiebel
Publikováno v:
Clinical Cancer Research. 10:3577-3585
Purpose: Vascular endothelial growth factor (VEGF) promotes acute myelogenous leukemia (AML) cell growth and survival and may contribute to drug resistance. bevacizumab, an anti-VEGF monoclonal antibody, exhibits clinical activity against diverse mal
Autor:
Maria R. Baer, Selina M. Luger, Kelly J. Norsworthy, Edward A. Sausville, Stephanie Fleckinger, Kenneth S. Bauer, Ivana Gojo, Michael L. Tidwell, Alexander E. Perl, Martin Carroll
Publikováno v:
Investigational new drugs. 31(5)
Background The PI3K-Akt pathway is frequently activated in acute leukemias and represents an important therapeutic target. UCN-01 and perifosine are known to inhibit Akt activation. Methods The primary objective of this phase I study was to determine
Autor:
Dan P. Zandberg, Jason Bierenbaum, Franklin Hendrick, Amy J. Davidoff, Emily J. Vannorsdall, Maria R. Baer, Yi Ning, Michael L. Tidwell, Xianfeng Frank Zhao
Publikováno v:
Leukemialymphoma. 54(2)
Little is known about disparities in myelodysplastic syndromes (MDS). We performed a retrospective chart review of patients with MDS (n = 252) evaluated at the University of Maryland Greenebaum Cancer Center between 2000 and 2010. The median age at d